Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.

Introduced

In Committee

Floor

Crossed Over

Passed

Enacted

Overview Bill text 1 History 1 Sponsors

No summary has been published for this bill. The full text is on the Bill text tab.

Chamber: House
Introduced: Apr 7, 2026
Last action: Apr 7, 2026 — Introduction and first reading, referred to Health Finance and Policy
Session: 2025-2026
Momentum: 28 · Low

PASSAGE PROBABILITY

1% Unlikely

Why this number

Stage base In Committee — base rate 2%, measured from MN's completed sessions
Momentum -5 28/100 from the pace of recorded action
Time since last action -22 188 days quiet

A transparent scoring model over stage, momentum, recency, sponsorship and recorded votes — not a trained predictor. Treat it as a way to rank attention, not as a forecast.